Proscia’s Concentriq AP-Dx is a comprehensive diagnostic software solution for viewing, interpreting, and managing whole slide images.
Proscia has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq AP-Dx. The digital pathology solution was cleared for the purpose of primary diagnosis.
In support of its 510(k) clearance, Proscia conducted a multi-site clinical study at PathGroup, South Bend Medical Foundation, and Spectrum Healthcare Partners. The study demonstrated that diagnoses made on Concentriq AP-Dx are non-inferior to traditional glass slide reads. Relative to ground truth data, the difference in major discordance rates for slides read digitally and for slides read using the microscope was -0.1%.
To learn more about Concentriq AP-Dx and see a live demo, register for Proscia’s webinar. “Welcome to Concentriq AP-Dx” will take place on Friday, March 8 at 12PM EST.
*Concentriq AP-Dx is cleared (K230839) for clinical use with the Hamamatsu NanoZoomer S360MD Slide scanner in the United States.
